Novartis Buys Rest of Alcon Stake for $12.9B

BASEL, Switzerland ( TheStreet) - Novartis

( NVS) will acquire the 23% of eye-care company Alcon ( ACL) it doesn't already own for $12.9 billion.

Novartis, the Swiss drugs company, will pay $168 a share for the stake, which is made up of 2.8 Novartis shares and contingent cash payment.

"The full merger is the logical conclusion of our initial strategic investment in Alcon. With this step Novartis takes full ownership, becoming the global leader in eye care, a rapidly expanding, innovative platform based on the growing needs of an aging population" said Daniel Vasella, chairman of Novartis, in a statement Wednesday.

The merger is expected to be completed during the first half of 2011.

Novartis said Wednesday it will fund the acquisition by issuing stock and through a stock buyback.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

More from Stocks

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says